Navigation Links
Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation
Date:2/23/2011

BETHESDA, Md., Feb. 23, 2011 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis, showed promising results in a Phase 3 clinical trial.

The trial was designed to evaluate patients age 12 and up who carry at least one copy of a CF mutation called G551D. The study included 161 patients who received at least one dose of VX-770 or placebo.

Patients who took the drug, compared to those on placebo, showed a marked improvement in lung function at 24 weeks, which was sustained for the duration of the 48-week trial.

Patients also showed improvement across all key secondary endpoints in the study, including reduced likelihood of experiencing a pulmonary exacerbation, decreased respiratory symptoms and improved weight gain. Each of these areas is critically important to the health of people with CF.

In addition, average sweat chloride levels of patients on VX-770 dropped toward normal levels, while those on placebo did not change—indicating the drug is impacting the underlying defect in CF. Excessive sweat chloride (salt) is a key clinical indicator of CF.

VX-770 is being developed by Vertex, and was discovered in collaboration with the CF Foundation, which provided substantial support to Vertex throughout the development process, including an approximately $75 million investment.

About four percent of people with CF carry the G551D mutation. More studies are needed to determine whether other CF mutations may benefit from VX-770.

"These results are highly encouraging. They provide scientific evidence that support our long-standing belief that targeting the underlying defect of CF may have a profound effect on the disease," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "We have much more to do to end the suffering caused by thi
'/>"/>

SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... YORK, Nov. 14, 2011 Reportlinker.com announces that ... its catalogue: Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title=,The ... Japan Test ... 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, ...
... Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage ... today that Punit Dhillon, President and CEO, will be ... in Irvine, California. (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO ) ... Forum Hyatt Regency Irvine 17900 Jamboree Road Irvine, ...
Cached Medicine Technology:The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 2The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 3The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 4The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 5OncoSec to Present at Medical Device Investor Forum 2
(Date:7/13/2014)... 2014 Epidemiologists forecast an increase in ... from 8,062 diagnosed incident cases in 2013 to 11,568 ... Rate (AGR) of 4.35%, during the forecast period. In ... diagnosed incident cases of aGVHD in the 6MM, with ... lowest number of diagnosed incident cases of aGVHD, with ...
(Date:7/13/2014)... ability to identify odors might indicate the development ... of the eye could indicate the build-up of ... brain, according to the results of four research ... Conference 2014 (AAIC 2014) in Copenhagen. , In ... identify odors was significantly associated with loss of ...
(Date:7/13/2014)... Wright & Schulte LLC has learned that ... July of 2015, in U.S. District Court, District of ... discovery process in the South Carolina federal court ... the multidistrict litigation (MDL). The complaints pending in the ... allege that they took the statin medication to lower ...
(Date:7/13/2014)... Celebrity fitness trainer and former World ... partnership with Aqua Health Labs for their flagship product ... . The collaboration was recently announced live on ESPN ... , actor, model, and a two time World Super ... he has prepared stars including Demi Moore, Hilary Swank ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that ... the Tamarack Senior Living Community in Palatine, IL. The group, ... the 3rd Wednesdays of every month. This group will ... located at 55 S. Greeley St. Palatine, IL 60067. ... no cost for the group. , “A grief support ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... By Mary Brophy Marcus HealthDay Reporter ... that,s typically used to treat the flu and Parkinson,s ... patients, a new study indicates. Traumatic brain injury ... to rehabilitation facilities after hospitalization were given amantadine hydrochloride. ...
... but long ago shelved after newer, modern antiretroviral therapies became ... uses its natural immunity to fight the viruswork that could ... published online this month by the journal PNAS , ... at the University of California, San Francisco (UCSF) presented the ...
... Feb. 29 (HealthDay News) -- Sports-related concussions are common in ... type of head injury, according to an expert. While ... immediate CT scan or MRI, concussion damage occurs at the ... scans of the brain, said Dr. Howard Derman, director of ...
... 29, 2012 - Scientists at the Toronto Western Research ... that protects the brain against the damaging effects of ... been in development for a few years. At this ... development among drugs created to reduce the brain,s vulnerability ...
... Scientists have combined two new "designer" forms of aspirin into ... its forebears in controlling the growth of several forms of ... so named because it releases nitric oxide (NO) and hydrogen ... Medicinal Chemistry Letters . Khosrow Kashfi, Ravinder Kodela and ...
... WEDNESDAY, Feb. 29 (HealthDay News) -- People worried about ... their life and their work performance, and their commitment ... questionnaires completed by 321 workers with an average age ... commercial distribution companies, or were temporary work agency employees. ...
Cached Medicine News:Health News:Drug Seems to Speed Recovery After Traumatic Brain Injury 2Health News:Drug Seems to Speed Recovery After Traumatic Brain Injury 3Health News:Drug Seems to Speed Recovery After Traumatic Brain Injury 4Health News:Old drug reveals new tricks 2Health News:Old drug reveals new tricks 3Health News:Sports Concussion: Myths and Facts 2Health News:Canadian scientist develops world's most advanced drug to protect the brain after a stroke 2
... instrument and custom filter wheels with ... The standard filter set includes: FAM/SYBR ... Red (585nm-610nm), Cy5 (635nm-665nm) and Cy3 ... analysis software, Beacon Designer oligo software, ...
... rapid, real-time thermal cycler used for identifying ... much of the testing process, and making ... the fastest, easiest to use, and most ... SmartCycler delivers highly accurate and consistent test ...
... SmartCycler System is a rapid, real-time thermal ... biological samples. By automating much of the ... individually programmable, it is the fastest, easiest ... on the market. The SmartCycler delivers highly ...
... The Applied Biosystems 7300 Real-Time ... real-time PCR capabilities with exceptional budget ... you to perform gene expression analysis, ... assays with internal positive controls ...
Medicine Products: